

1  
2 **MR Imaging Distinguishes Tumor Hypoxia Levels of**  
3 **Different Prognostic and Biological Significance in**  
4 **Cervical Cancer**

5  
6 Tiril Hillestad<sup>1</sup>, Tord Hompland<sup>1,2</sup>, Christina S. Fjeldbo<sup>2</sup>, Vilde E. Skingen<sup>2</sup>, Unn Beate Salberg<sup>2</sup>,  
7 Eva-Katrine Aarnes<sup>2</sup>, Anja Nilsen<sup>2</sup>, Kjersti V. Lund<sup>3</sup>, Tina S. Evensen<sup>1</sup>, Gunnar B. Kristensen<sup>4,5</sup>,  
8 Trond Stokke<sup>1,2</sup>, and Heidi Lyng<sup>2,6</sup>

9  
10 <sup>1</sup>Department of Core Facilities, Norwegian Radium Hospital, Oslo University Hospital, Oslo,  
11 Norway. <sup>2</sup>Department of Radiation Biology, Norwegian Radium Hospital, Oslo University  
12 Hospital, Oslo, Norway. <sup>3</sup>Department of Radiology, Norwegian Radium Hospital, Oslo  
13 University Hospital, Oslo, Norway. <sup>4</sup>Department of Gynecological Oncology, Norwegian  
14 Radium Hospital, Oslo University Hospital, Oslo, Norway. <sup>5</sup>Institute of Cancer Genetics and  
15 Informatics, Oslo University Hospital, Oslo, Norway, <sup>6</sup>Department of Physics, University of  
16 Oslo, Oslo, Norway.

17  
18 T. Hillestad and T. Hompland share equal authorship of this article.

19  
20 **Running Title:** Imaging of Tumor Hypoxia Levels

21  
22 **Correspondent Author:** Heidi Lyng, Department of Radiation Biology, Norwegian Radium  
23 Hospital, Oslo University Hospital, Pb 4953 Nydalen, 0424 Oslo, Norway.

24 Phone: 47-2278-1478; Fax: 47-2278-1495; Email: [heidi.lyng@rr-research.no](mailto:heidi.lyng@rr-research.no).

25  
26 The gene expression data have been deposited to the GEO repository; GSE72723 (patient  
27 data), GSE147384 (cell line data, will be released at publication).

28  
29 **NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.**

30 **Abstract**

31  
32 Tumor hypoxia levels range from mild to severe and have different biological and  
33 therapeutical consequences, but are not easily assessable in patients. We present a method  
34 based on diagnostic dynamic contrast enhanced (DCE) magnetic resonance imaging (MRI)  
35 that visualizes a continuous range of hypoxia levels in tumors of cervical cancer patients.  
36 Hypoxia images were generated using an established approach based on pixel-wise  
37 combination of the DCE-MRI parameters  $v_e$  and  $K^{trans}$ , reflecting oxygen consumption and  
38 supply, respectively. An algorithm to retrieve hypoxia levels from the images was developed  
39 and validated in 28 xenograft tumors, by comparing the MRI-defined levels with hypoxia  
40 levels derived from pimonidazole stained histological sections. We further established an  
41 indicator of hypoxia levels in patient tumors based on expression of nine hypoxia responsive  
42 genes. A strong correlation was found between these indicator values and the MRI-defined  
43 hypoxia levels in 63 patients. Chemoradiotherapy outcome of 74 patients was most strongly  
44 predicted by moderate hypoxia levels, whereas more severe or milder levels were less  
45 predictive. By combining gene expression profiles and MRI-defined hypoxia levels in cancer  
46 hallmark analysis, we identified a distribution of levels associated with each hallmark;  
47 oxidative phosphorylation and G<sub>2</sub>/M checkpoint were associated with moderate hypoxia,  
48 and epithelial-to-mesenchymal transition and inflammatory responses with significantly  
49 more severe levels. At the mildest levels, interferon response hallmarks, together with  
50 stabilization of HIF1A protein by immunohistochemistry, appeared significant. Thus, our  
51 method visualizes the distribution of hypoxia levels within patient tumors and has potential  
52 to distinguish levels of different prognostic and biological significance.

53  
54  
55  
56  
57  
58  
59  
60

## 61 **Introduction**

62 Solid tumors show a highly heterogeneous oxygen distribution with hypoxia levels ranging  
63 from mild to moderate and severe (1). The hypoxia level determines resistance to cancer  
64 therapies like radiation, chemotherapy and many molecular targeting drugs (1–4), and may  
65 therefore have large therapeutical consequences. Current understanding of how the  
66 different levels drive cancer progression and affect treatment response is scarce and mostly  
67 based on experimental studies (5–7). At mild hypoxia, around 2% O<sub>2</sub>, activation of the  
68 hypoxia inducible transcription factor HIF1 promotes metabolic reprogramming and cell  
69 survival (8,9), more severe levels, below 1% O<sub>2</sub>, may impair cell proliferation and lead to  
70 genomic instability (10,11), and below 0.5% O<sub>2</sub> the cytotoxic effect of radiation is more than  
71 2-fold reduced (2). Hypoxia may also induce epithelial-mesenchymal-transition (EMT) and  
72 immune evasion of tumor cells (12,13), but the levels of importance for these processes  
73 have not been clarified. In patient tumors, earlier investigations using invasive electrodes to  
74 measure oxygen partial pressure (pO<sub>2</sub>) have shown considerable differences across cancer  
75 types in the level most strongly associated with treatment outcome, ranging from 2.5-10  
76 mmHg or approximately 0.3-1.3% O<sub>2</sub> (14). More recent clinical work has almost exclusively  
77 focused on the presence or absence of hypoxia (15), mainly because oxygen electrodes are  
78 not feasible and alternative approaches to assess hypoxia levels are lacking. A method based  
79 on medical imaging would facilitate investigations of how individual levels relate to  
80 treatment outcome and tumor biology in patients, and help development of more efficient  
81 therapies to combat hypoxia.

82  
83 Hypoxia occurs in tumors due to impaired oxygen supply by a chaotic vascular network  
84 and/or elevated oxygen consumption in regions with high cellularity (1). We recently  
85 presented a tool for pixel-wise combination of images reflecting oxygen consumption with  
86 images reflecting oxygen supply into images representing hypoxia (16). The consumption  
87 and supply based hypoxia (CSH)-imaging tool was originally developed in prostate cancer  
88 patients, using images of the apparent diffusion coefficient (ADC) and fractional blood  
89 volume (fBV) derived from diffusion weighted (DW) magnetic resonance (MR) images. The  
90 information in the two images was utilized to reflect the difference between oxygen  
91 consumption and supply and thereby the probability of each pixel to locate in a hypoxic  
92 region. Although only the presence of hypoxia was addressed in this study, it is likely that a

93 difference between oxygen consumption and supply within a tumor region also would  
94 provide information on the hypoxia level. The CSH-principle may therefore be a basis for  
95 establishing an imaging approach for quantifying hypoxia levels.

96

97 Locally advanced cervical cancer is a disease for which better biological understanding and  
98 new therapeutical approaches to overcome hypoxia are urgent (17,18). In the present work,  
99 we aimed to construct images that visualize a continuous distribution of hypoxia levels in  
100 cervical tumors by applying the CSH-tool. Our approach was based on dynamic contrast  
101 enhanced (DCE)-MR imaging (MRI), because this modality is state-of-the-art diagnostics for  
102 the disease. We showed that the DCE-MRI parameters  $v_e$  and  $K^{trans}$  from the Tofts  
103 pharmacokinetic model (19) reflected oxygen consumption and supply, respectively, and  
104 could be successfully combined to generate hypoxia images in xenograft and patient tumors.  
105 We further developed an algorithm to assign hypoxia levels to all pixels. The algorithm was  
106 validated by comparison with hypoxia levels determined from pimonidazole stained sections  
107 in xenograft tumors and hypoxia related gene expression in patient tumors. The power of  
108 this approach was demonstrated by presenting the distribution of hypoxia levels in tumors  
109 of 74 patients and identifying significant differences in the levels associated with treatment  
110 outcome and a set of cancer hallmarks.

111

## 112 **Materials and Methods**

### 113 **Clinical cohort**

114 Totally 74 patients with locally advanced cervical carcinoma, prospectively recruited to our  
115 chemoradiotherapy protocol at the Norwegian Radium Hospital were included  
116 (Supplementary Table S1). Gene expression profiles and a gene score reflecting hypoxia  
117 were available from previous work (20) for 63 patients, and paraffin embedded tissue  
118 sections for immunohistochemistry were available for 73 patients. The gene score was based  
119 on the expression level of 6 hypoxia responsive genes and increased with increasing amount  
120 of hypoxia (20). All patients received external radiotherapy combined with cisplatin (40  
121 mg/m<sup>2</sup> weekly) followed by intracavitary brachytherapy and follow up as described (20). The  
122 study was approved by the Regional Committee for Medical Health Research Ethics in  
123 southern Norway, and written informed consent was attained from all patients.

124

## 125 **Cell lines and hypoxia treatment**

126 HeLa and SiHa cervical cancer cell lines from American Type Culture Collection were used.  
127 Confirmation of cell line identity and cell culturing were performed as described (21).  
128 Totally  $1.5 \cdot 10^6$  HeLa and  $1.7 \cdot 10^6$  SiHa cells were reseeded in 10 cm plastic dishes 24 hours  
129 before exposure to hypoxia at 0.2%, 0.5%, 1%, 2% and 5% O<sub>2</sub> for 24 hours at 37°C, all with  
130 5% CO<sub>2</sub>, by using an Invivo<sub>2</sub>200 chamber (Ruskin Technology Ltd). Normoxic controls  
131 (95% air, 5% CO<sub>2</sub>) were included for all hypoxia experiments.

132

## 133 **Human tumor xenografts**

134 HeLa and SiHa cervical cancer xenograft tumors were established in female nude mice, bred  
135 at the animal department of our institute and kept in specific pathogen-free environment,  
136 with food and water supplied ad libitum. Totally  $1 \cdot 10^6$  HeLa cells in 20 µl or  $2 \cdot 10^6$  SiHa cells in  
137 40 µl of Hank's balanced salt solution were injected intramuscularly in both hind legs of  
138 adult mice. Tumor growth was monitored with anatomical T<sub>2</sub>-weighted MRI. At the day of  
139 DCE-MRI, the hypoxia marker pimonidazole (60 mg/kg; Hydroxyprobe, Inc) was administered  
140 intraperitoneally prior to MR scanning in 16 HeLa and 12 SiHa tumors. After the scan, 90-120  
141 minutes after pimonidazole injection, the mice were euthanized by dislocation of the neck,  
142 and the tumors were excised, formalin-fixed and paraffin-embedded for  
143 immunohistochemistry. All procedures were approved by the Norwegian Animal Research  
144 Authority and performed in accordance with the guidelines on animal welfare of the  
145 Federation of Laboratory Animal Science Associations.

146

## 147 **DCE-MRI**

148 DCE-MRI of xenograft tumors was performed at a volume of 100-800 mm<sup>3</sup>, using a 7.05 T  
149 Biospec bore magnet (Bruker) and a fast bolus injection of 5.0 ml/kg body weight of Gd-  
150 DOTA (Dotarem, Guerbet) (Supplementary Method S1). Totally 8 images prior to and 57  
151 images post injection of Gd-DOTA were acquired with an axial T<sub>1</sub>-weighted spoiled gradient  
152 recalled sequence (SPGR). The images had a spatial resolution of 234x234x1000 µm<sup>3</sup>. The  
153 three most central tumor slices were used in the analysis.

154

155 In patients, DCE-MRI was performed at diagnosis, using a 1.5 T Signa Horizon LX tomograph  
156 (GE Medical Systems) with a pelvic phased array coil and a fast bolus injection of 0.1

157 mmol/kg body weight Gd-DTPA (Magnevist, Schering) (Supplementary Method S1). Totally  
158 1-2 series prior to and 12-13 series post injection of Gd-DTPA were acquired with an axial T<sub>1</sub>-  
159 weighted SPGR sequence. The images had a pixel size of 780x780 μm<sup>2</sup>, slice thickness of 5  
160 mm and slice gap of 1 mm. All slices containing tumor were used in the analysis.

161

## 162 Hypoxia images

163 The tumors were outlined in T<sub>2</sub>-weighed MR images and co-registered with the DCE-MR  
164 images. Pharmacokinetic analysis of the contrast uptake curves obtained from the DCE-MR  
165 images was performed on a pixel-by-pixel basis using the Tofts model (19) (Supplementary  
166 Methods S1), and parametric images of  $K^{trans}$  and  $v_e$  were generated. To construct hypoxia  
167 images, the CSH-tool was applied on the  $K^{trans}$  and  $v_e$  images as described for DW-MRI (16).  
168 Hence, pixel-wise plots of  $K^{trans}$  versus  $v_e$  were generated for each tumor, representing  
169 decreasing oxygen consumption on the horizontal  $v_e$ -axis and increasing oxygen supply on  
170 the vertical  $K^{trans}$ -axis. To determine a threshold for hypoxia, a line discriminating pixels in  
171 hypoxic and non-hypoxic regions, and thus defining the hypoxic fraction, was determined in  
172 an iterative procedure with all tumors, using an independent hypoxia measure as learning  
173 variable. The hypoxic fraction was calculated for each tumor and iteration and correlated  
174 with the independent hypoxia measure. The optimal line was determined by the highest  
175 Pearson correlation coefficient and was described by its intersections with the horizontal  
176 ( $v_{e0}$ ) and vertical axes ( $K_0^{trans}$ ).

177

## 178 Immunohistochemistry and digital histopathology

179 Adjacent sections, 4-5 μm thick, from xenograft tumors were stained for hypoxia (n=28)  
180 using a pimonidazole polyclonal rabbit antibody (1:3500; Hydroxyprobe Inc.) and endothelial  
181 cells (n=26), using a CD31 rabbit polyclonal antibody (1:50, ab28364; Abcam). Hematoxylin  
182 was used as counterstain to visualize cell nuclei. Digital histopathology was performed to  
183 quantify hypoxic fraction ( $HF_{Pimo}$ ), cell density (CD) and blood vessel density (BVD)  
184 (Supplementary Method S1). Sections from 73 patient tumors were stained with the  
185 monoclonal mouse HIF1A antibody clone 54 (1:25, no. 610958; BD Transduction  
186 Laboratories) as described (21). Percentage of HIF1A positive tumor cells was scored  
187 manually based on nuclear staining: 0, 0%; 1, 1-10%; 2, 11-25%; 3, 26-50%; 4, 51-75% and 5,  
188 >75%.

189 **Gene expression**

190 Gene expression profiling of HeLa and SiHa cells exposed to hypoxia at 0.2%, 0.5%, 1%, 2%  
191 and 5% O<sub>2</sub> and normoxia (95% air) was carried out using Illumina bead arrays HT-12 v4  
192 (Illumina Inc.). Total RNA was isolated using miRNeasy MiniKit (Qiagen). Complementary  
193 RNA was synthesized, labeled and hybridized to the arrays. Signal extraction and quantile  
194 normalization were performed using software provided by the manufacturer (Illumina Inc.).  
195 The data were deposited in the Gene Expression Omnibus (GEO; GSE147384). Normalized  
196 gene expression profiles of 63 patients, generated previously using Illumina bead arrays  
197 WG-6 v3 (Illumina Inc.) (20), were downloaded from GEO (GSE72723).

198

199 **Statistical analysis**

200 To compare hypoxic fractions derived from MR images and pimonidazole stained sections,  
201 an adapted version of Pearson product moment correlation test for similarity between two  
202 data sets was applied (22):

203

204 
$$\text{Similarity}(x, y) = \frac{\sum(x-\bar{x})(y-\bar{y})}{\frac{(n-1)}{2}(\text{var}(x)+\text{var}(y))}$$

205

206 where  $x$  and  $y$  are sets of hypoxic fractions from MRI and pimonidazole, respectively,  $\text{var}(x)$   
207 and  $\text{var}(y)$  are their sample variance and  $n$  is sample size. The function is equal to one when  
208 the hypoxic fractions from the two modalities are perfectly correlated with a slope of one. In  
209 cases of poor correlation or a slope deviating from one, the similarity decreases.

210

211 Curve fitting was performed through regression analysis. Student's t-test was used for  
212 comparison of groups when data complied conditions of normality and equal variance.  
213 Otherwise, Wilcoxon rank sum test was used. Linear correlations were searched for by  
214 Pearson correlation test. Clinical endpoint was progression-free survival defined as time  
215 from diagnosis to disease-related death or first occurrence of relapse. Patients were  
216 censored at their last appointment or at 5 years. Cox univariate proportional hazard analysis  
217 was performed, and Kaplan-Meier curves were compared using log-rank test. Probability  
218 values of  $P < 0.05$  were considered significant. The statistical analyses were performed using  
219 SigmaPlot and SPSS.

## 220 Results


### 221 MRI-based hypoxia images provide measures of hypoxic fraction

222 The possibility to construct hypoxia images from DCE-MR images was investigated in  
223 xenograft tumors by first examining whether the histopathology parameters cell density  
224 (CD) and blood vessel density (BVD) could be used to reflect oxygen consumption and  
225 supply, respectively. Images of the DCE-MRI parameters  $v_e$  and  $K^{trans}$  displayed resemblance  
226 with those of CD and BVD, respectively, with some disagreement possibly due to a two-  
227 hundred fold difference in slice thickness (Supplementary Fig. S1). Consistent with these  
228 observations, significant correlations were found between median values of  $v_e$  and CD  
229 ( $R^2=0.46$ ,  $P<0.0005$ ) and between median values of  $K^{trans}$  and BVD ( $R^2=0.17$ ,  $P=0.03$ )  
230 (Supplementary Fig. S1). No significant correlation was found between  $v_e$  and BVD or  
231 between  $K^{trans}$  and CD (Supplementary Fig. S2A). Hypoxic fraction determined by  
232 pimonidazole staining ( $HF_{Pimo}$ ) was correlated with both  $v_e$  ( $R^2=0.46$ ,  $P<0.00005$ ) and  $K^{trans}$   
233 ( $R^2=0.22$ ,  $P<0.05$ ; Supplementary Fig. S2B).  $v_e$  and  $K^{trans}$  therefore seemed to be connected  
234 to hypoxia and contain different information related to oxygen consumption and supply,  
235 respectively, in line with other reports where low molecular weight contrast agents are used  
236 for DCE-MRI (23).

237

238 Based on the above results, we searched to construct hypoxia images in xenograft tumors by  
239 combining images of  $v_e$  and  $K^{trans}$  and using  $HF_{Pimo}$  as independent measure of hypoxia. In  
240 pixel-wise plots of  $K^{trans}$  versus  $v_e$ , pixels from tumors having a high  $HF_{Pimo}$  were in general  
241 located more towards the lower left corner than pixels from tumors with a low  $HF_{Pimo}$  (Fig.  
242 1A, B), consistent with the CSH-principle. The line that best discriminated pixels in hypoxic  
243 and non-hypoxic regions for all tumors combined was determined (Supplementary Fig. S3A).  
244 Pixels below the optimal line were considered hypoxic and the fraction of these pixels,  $HF_{MRI}$ ,  
245 was strongly correlated to  $HF_{Pimo}$  ( $R^2=0.57$ ,  $P<0.000005$ ; Fig. 1C). This correlation was  
246 stronger than between  $v_e$  or  $K^{trans}$  and  $HF_{Pimo}$  (Supplementary Fig. S2). The resulting binary  
247 hypoxia images showed strong resemblance to the pimonidazole stained sections (Fig. 1B,  
248 D).





249  
250

251 **Figure 1.** Construction of hypoxia images in xenograft and patient tumors. **A**, Pixel-wise plot  
252 of  $K^{trans}$  versus  $v_e$  for a xenograft tumor with high hypoxic fraction according to pimonidazole  
253 staining ( $HF_{Pimo}$ ) (red) and another with low  $HF_{Pimo}$  (blue). The optimal discrimination line  
254 separating pixels in hypoxic and non-hypoxic regions is shown. **B**, Pimonidazole stained  
255 sections of the tumors presented in **A**. **C**, Scatter plot of  $HF_{MRI}$  versus  $HF_{Pimo}$  for 28 xenograft  
256 tumors based on the optimal discrimination line. **D**, Binary hypoxia images visualizing  $HF_{MRI}$   
257 of the tumors presented in **A** and **B**. **E**, Scatter plot of  $HF_{MRI}$  versus hypoxia gene score for 63  
258 patient tumors based on the optimal discrimination line. **F**, Binary hypoxia images visualizing  
259  $HF_{MRI}$  of a less and more hypoxic tumor according to the hypoxia gene score. **C**, **E**,  $P$ -value  
260 and correlation coefficient ( $R^2$ ) from linear correlation analysis are shown. **D**, **F**, The binary  
261 images are overlaid on axial T<sub>2</sub>-weighted images.

262

263 To confirm applicability of the CSH-tool to produce hypoxia images in patient tumors, pixel-  
264 wise plots of  $K^{trans}$  versus  $v_e$  were generated from the clinical images. Similar to what we

265 observed in xenografts, pixels from hypoxic tumors appeared to be located towards the  
266 lower left corner in these plots (Supplementary Fig. S4). By using the same procedure as  
267 above and the gene score from previous work (20) as independent hypoxia measure, an  
268 optimal line to discriminate pixels in hypoxic and non-hypoxic regions for all tumors  
269 combined was determined (Supplementary Fig. S3B) and a  $HF_{MRI}$  was calculated for each  
270 tumor. A strong correlation between  $HF_{MRI}$  and the hypoxia gene score ( $R^2=0.27$ ,  $P<0.00001$ ;  
271 Fig. 1E, F) was found. This correlation was stronger than between  $v_e$  or  $K^{trans}$  and the gene  
272 score (Supplementary Fig. S5A). In analysis of all 74 patients,  $HF_{MRI}$  was strongly correlated  
273 with progression-free survival, where patients with high  $HF_{MRI}$  had a poor outcome  
274 compared to the others ( $P=0.0014$ ; Supplementary Fig. S5B), consistent with the prognostic  
275 significance of the gene score (20). The correlation to outcome was weaker for  $K^{trans}$  or  $v_e$   
276 ( $P=0.015$  and  $P=0.074$ , respectively; Supplementary Fig. S5B). All together, this showed that  
277 hypoxia images could be constructed using the DCE-MRI parameters  $v_e$  and  $K^{trans}$  as input to  
278 the CSH-tool.

279


### 280 **Hypoxia levels defined by pimonidazole staining in xenograft tumors are visualized by MRI**

281 Based on the hypoxia images, an algorithm to assign a hypoxia level to each individual pixel  
282 was developed. We hypothesized that the location of a pixel in plots of  $K^{trans}$  versus  $v_e$ ; *i.e.*,  
283 the distance from the pixel to the optimal discrimination line, depends on the hypoxia level  
284 of the corresponding tumor region (Fig. 2A). This hypothesis is likely because the line  
285 represents the weighted information of  $K^{trans}$  (oxygen supply) and  $v_e$  (oxygen consumption)  
286 underlying the level of the independent hypoxia measure. The hypoxia level,  $HL_{MRI}$ , can thus  
287 be expressed as:

$$288 \quad HL_{MRI} = (-1) * \frac{\left(\frac{K^{trans}}{K_0^{trans}} + \frac{v_e}{v_{e0}}\right) - 1}{\sqrt{\left(\frac{1}{K_0^{trans}}\right)^2 + \left(\frac{1}{v_{e0}}\right)^2}}$$

289

290 where the level of the optimal line, described by the intersection points  $v_{e0}$  and  $K_0^{trans}$ , was  
291 set to zero, and increasing values of  $HL_{MRI}$  indicated more severe hypoxia. Application of the  
292 algorithm to calculate four hypoxia levels is shown in Figure 2B, together with the underlying  
293  $HL_{MRI}$  image (Fig. 2C).



294  
295

296 **Figure 2.** Indicator of hypoxia levels in xenograft tumors. **A**, Principle of assessing hypoxia  
297 levels ( $HL_{MRI}$ ) from hypoxia images as the distance from the pixel to the optimal  
298 discrimination line ( $HL_{MRI}=0$ ). **B**, Pixel-wise plot of  $K^{trans}$  versus  $v_e$  of a xenograft tumor. The  
299 solid line indicates the optimal discrimination line ( $HL_{MRI}=0$ ), whereas the stippled lines in  
300 parallel represent three different hypoxia levels; i.e. different  $HL_{MRI}$  values. Points are color-  
301 coded according to their  $HL_{MRI}$  value. **C**, Hypoxia image of the tumor presented in **B**, overlaid  
302 on an axial  $T_2$ -weighted image. **D**, Pimonidazole staining intensity in histological sections  
303 from a xenograft tumor versus distance from necrosis. The histological section is shown  
304 above. **E**, Pimonidazole stained section of the tumor presented in **B** and **C**. **F**, Color coded  
305 pimonidazole-based image of hypoxia levels,  $HL_{Pimo}$ , for the tumor presented in **B**, **C** and **E**.


306  
307

308 A procedure to extract hypoxia levels from pimonidazole stained tumor sections in  
309 xenografts was developed for validation of the algorithm. *In vitro* studies have shown that  
310 the binding efficacy of pimonidazole during hypoxia increases exponentially with decreasing  
311 oxygen concentrations (24). In line with this, the pimonidazole staining intensity was  
312 generally strongest close to necrotic regions (anoxia) and decreased with increasing distance  
313 from necrosis (Fig. 2D), most likely reflecting a hypoxia gradient. We therefore assumed that  
314 the staining intensity was proportional to hypoxia level, and produced pimonidazole-based

315 images of hypoxia levels ( $HL_{Pimo}$ ) that were used for validation (Fig. 2E, F; Supplementary  
316 Method S1). Visual inspection showed large resemblance between the  $HL_{MRI}$  and  $HL_{Pimo}$   
317 images (Fig. 2C, F), although there was a considerable difference in slice thickness between  
318 the two modalities. By this inspection, we further found that the staining intensity in  
319 pimonidazole-based images could be evaluated down to a  $HL_{Pimo}$  of 0.38. Below this limit,  
320 the intensity was weak with small changes, probably reflecting non-hypoxic levels.

321  
322 Hypoxia levels derived from MR- and pimonidazole-based images (Fig. 2C, F) were compared  
323 in 28 xenografts. By varying the threshold for  $HL_{MRI}$ , from 0.11 in severe hypoxia to -0.05 at  
324 the mildest level, and for  $HL_{Pimo}$ , from 2.6 at the strongest staining intensity to 0.01 in the  
325 weakly stained region, we generated sets of hypoxic fractions (% of tumor  $> HL_{MRI}$  or  $HL_{Pimo}$ )  
326 for both modalities and all xenografts (Fig. 3A). The two data sets, each consisting of 28x200  
327 hypoxic fractions, were first compared using similarity analysis, where we for each  $HL_{MRI}$   
328 threshold identified the  $HL_{Pimo}$  threshold that led to the highest similarity between hypoxic  
329 fraction derived by the two modalities (Fig. 3B). Overall, the similarity values were high  
330 ( $>0.6$ ) and an exponential relationship was observed between the similarity-matched  $HL_{MRI}$   
331 and  $HL_{Pimo}$ . The exponential relationship, presented as a linear relationship in a log plot in  
332 Figure 3C, is in line with the exponential binding of pimonidazole with decreasing oxygen  
333 concentrations (24). Correlation analysis of the most similar hypoxic fractions provided an  
334 indication of how well  $HL_{MRI}$  reflected the different hypoxia levels. A strong correlation  
335 ( $P<0.001$ ) was found for  $HL_{MRI}$  in the range of -0.03 to 0.1. Hence, hypoxic fraction from a  
336 large range of levels could be measured. Moreover, within this range the mean hypoxic  
337 fraction based on all 28 xenograft tumors showed considerable differences, ranging from  
338 0.38 at mild hypoxia ( $HL_{MRI}=-0.03$ ; Fig. 3D) to 0.07 at more severe hypoxia ( $HL_{MRI}=0.06$ ; Fig.  
339 3E) and 0.02 at the most severe levels ( $HL_{MRI}=0.1$ ; data not shown). These results supported  
340 that our algorithm to image hypoxia levels was reliable. Further, the MRI-defined hypoxia  
341 levels could distinguish a large range of hypoxic fractions in xenograft tumors.

342



343

344 **Figure 3.** Assessing hypoxia levels in xenograft tumors. **A** Examples of binary MR- and  
 345 pimonidazole-based images, visualizing hypoxic fractions for four different  $HL_{MRI}$  and  $HL_{Pimo}$   
 346 thresholds of the tumor presented in **Fig. 2C** and **2F**. **B**, Similarity plots for the  $HL_{MRI}$   
 347 thresholds indicated in **A**, showing the similarity between MRI- and pimonidazole-based  
 348 hypoxic fractions *versus*  $HL_{Pimo}$  threshold. The highest similarity is marked for each  $HL_{MRI}$   
 349 threshold. **C**,  $HL_{MRI}$  *versus*  $HL_{Pimo}$  in 28 xenograft tumors. Similarity-matched  $HL_{MRI}$  and  $HL_{Pimo}$ ;  
 350 i.e.,  $HL_{MRI}$  and  $HL_{Pimo}$  leading to the highest similarity in the analysis presented in **B**, are  
 351 shown. The four  $HL_{MRI}$  thresholds shown in **A** are indicated with solid symbols together with  
 352 the correlation coefficient ( $R^2$ ) and curve from linear correlation analysis. **D**, **E**, Scatterplots  
 353 of MRI-based versus pimonidazole-based hypoxic fraction for a  $HL_{MRI}$  threshold of -0.03 (**D**)  
 354 and 0.06 (**E**). Similarity-matched  $HL_{MRI}$  and  $HL_{Pimo}$  were used to calculate hypoxic fractions for  
 355 28 xenograft tumors.  $P$ -value, correlation coefficient ( $R^2$ ) and curve from linear correlation  
 356 analysis are shown.

357

### 358 Hypoxia levels defined by gene expression in patient tumors are visualized by MRI


359 To confirm the validity of our algorithm in patient tumors, we constructed an indicator of  
 360 hypoxia levels based on the expression of hypoxia responsive genes. We utilized that genes  
 361 may be activated and, thus, show increased expression, at specific oxygen concentrations



362 (25). Nine indicator genes were selected among 31 previously identified hypoxia responsive  
363 genes in cervical cancer (21) (Supplementary Document S1). The genes are known to be  
364 regulated by HIF1 (*AK4*, *PFKFB4*, *P4HA2*), by both HIF1 and the unfolded protein response  
365 (*STC2*, *ERO1A*) or the regulation mechanisms are poorly explored (*UPK1A*, *KCTD11*, *SNTA1*,  
366 *PYGL*). By exposure of SiHa and HeLa cells to oxygen concentrations in the range of 0.2-21%  
367 O<sub>2</sub>, the concentration for half-maximal response was recorded for each gene (Fig. 4A, B), in a  
368 similar way as described for stabilization of HIF1A protein (8). This cell line derived hypoxia  
369 activation level was found to range from 0.55% to 1.81% O<sub>2</sub>, where the HIF1A targets *AK4*  
370 and *PFKFB4* had the highest level, in line with an HIF1 activation level of 1.5-2.0% O<sub>2</sub> (8) (Fig.  
371 4C, Supplementary Document S1). Thus, the indicator genes showed a range of levels likely  
372 to be found in human tumors (6) and broad enough for testing our algorithm.

373  
374 *HL<sub>MRI</sub>* images were constructed for all 74 patient tumors (Fig. 4D). Using the same strategy as  
375 for xenografts, a set of 200 hypoxic fractions was calculated for each tumor using *HL<sub>MRI</sub>*  
376 thresholds ranging from 0.1 in severe hypoxia to -0.3 as the mildest level. Expression data of  
377 the nine indicator genes were further retrieved from the gene expression profiles of each  
378 tumor. A correlation analysis of the two data sets was performed, where we for each  
379 indicator gene identified the *HL<sub>MRI</sub>* threshold that led to the strongest association between  
380 hypoxic fraction and expression (Fig. 4E; Supplementary Document S1). These *HL<sub>MRI</sub>*  
381 thresholds showed a strong correlation to the cell line derived hypoxia activation level for  
382 the nine indicator genes (Fig. 4F;  $R^2=0.84$ ,  $P<0.0005$ ). Although oxygen concentrations found  
383 for half-maximal response in cell lines are not directly transferable to patient tumors, this  
384 relationship together with the above xenograft results strongly supported that *HL<sub>MRI</sub>*  
385 provided a continuous, linear measure of hypoxia levels in tumors.

386  
387  
388  
389  
390  
391  
392  
393  
394  
395




396 **Figure 4.** Assessing hypoxia levels in patient tumors. **A, B,** Gene expression in HeLa (**A**) and  
 397 SiHa (**B**) cell lines *versus* the logarithm of oxygen concentration for two indicator genes,  
 398 *KCTD11* and *PKFKB4*. The expression levels are plotted relative to the level of normoxic  
 399 controls (21%  $O_2$ ). Hypoxia activation level and curve from linear correlation analysis are  
 400 indicated for each gene. **C,** Hypoxia activation level of nine indicator genes. Bars, range of  
 401 data for SiHa and HeLa cell line. **D,** Hypoxia level image of a patient tumor overlaid on an  
 402 axial  $T_2$ -weighted image. **E,** P-value in correlation analysis of hypoxic fraction calculated for a  
 403 set of 200  $HL_{MRI}$  thresholds *versus* gene expression in 63 patients, plotted as a function of  
 404  $HL_{MRI}$ . Data for two indicator genes, *KCTD11* and *PKFKB4* are shown. The  $HL_{MRI}$  value leading  
 405 to the strongest correlation between gene expression and MRI-based hypoxic fraction (*i.e.*,  
 406 lowest  $P$ -value) is indicated for each gene. **F,**  $HL_{MRI}$  for the strongest correlation achieved in **E**  
 407 *versus* hypoxia gene activation level in cell lines for nine indicator genes. Point and bar,  
 408 average value and range for SiHa and HeLa cell lines. Curve,  $P$ -value and correlation  
 409 coefficient ( $R^2$ ) from linear correlation analysis are shown.

410

#### 411 Hypoxia levels of prognostic significance are distinguished in MR images

412 The relationship presented in Figure 4F provided a tool to relate MRI defined hypoxia levels  
 413 to biological information derived in cell lines. Aided by this relationship, we defined  
 414 approximate  $HL_{MRI}$  intervals for severe, moderate and mild hypoxia in order to characterize  
 415 the hypoxia level distribution in patient tumors (Fig. 5A). The definitions corresponded  
 416 roughly to those proposed by others (6). Median  $HL_{MRI}$  of all tumors combined was -0.08.  
 417 This value was related to a cell line derived level of 1.3%  $O_2$  (Fig. 5A) and within the

418 moderate hypoxia range. However, the median value differed considerably across tumors,  
 419 ranging from -0.22 (2.3% O<sub>2</sub>) in mild hypoxia to 0.004 (0.8% O<sub>2</sub>) in moderate hypoxia. A pie  
 420 chart of each tumor was generated to visualize these differences, showing fraction of pixels  
 421 within  $HL_{MRI}$  intervals of 0.05 (Fig. 5B; Supplementary Fig. S6). Most tumors contained a  
 422 range from severe to non-hypoxic levels, however, fraction of the different levels varied  
 423 considerably across patients.



443 **Figure 5.** Hypoxia levels in patient tumors in relation to treatment outcome. **A**, Approximate  
 444  $HL_{MRI}$  intervals for severe, moderate and mild hypoxia based the relationship between  $HL_{MRI}$   
 445 and hypoxia gene activation level in cell lines presented in **Fig. 4F**. Stippled lines indicate  
 446 median hypoxia level ( $HL_{MRI}=-0.08$ ) for all patient tumors combined and the hypoxia level  
 447 with the strongest correlation to progression free survival ( $HL_{MRI}=0.01$ ) in the analysis  
 448 presented in **C**. **B**, Pie charts showing fractions of pixels with  $HL_{MRI}$  within the indicated  
 449 intervals for four tumors with different distribution of hypoxia levels. **C**, P-value in Cox  
 450 regression analysis of hypoxic fraction calculated for increasing  $HL_{MRI}$  threshold (increasing  
 451 severity level) versus progression-free survival, plotted as a function of  $HL_{MRI}$ . Horizontal  
 452 stippled line indicates a significance level of 0.05. Vertical stippled line indicates  $HL_{MRI}$  for the  
 453 strongest correlation ( $HL_{MRI}=0.01$ ). **D**, Kaplan Meier curves for progression-free survival of 74  
 454 patients with low (solid line) and high (stippled line) hypoxic fraction based on the  $HL_{MRI}$   
 455 threshold of 0.01 indicated in **C**. Patients were divided with 1/3 in the high-risk and 2/3 in  
 456 the low-risk group based on an expected failure rate 30%. P-value in log-rank test is shown.



457 To address whether differences seen in the pie charts across patients were associated with  
458 differences in chemoradiotherapy outcome, hypoxic fraction was determined for a range of  
459  $HL_{MRI}$  thresholds for each tumor and included in survival analysis with progression-free  
460 survival as end point. The strongest association to outcome was found for hypoxic fractions  
461 below a  $HL_{MRI}$  threshold of 0.01 (Fig. 5C), which was related to a cell line derived level of  
462 0.7%  $O_2$  and in moderate hypoxia close to the interval of severe hypoxia (Fig. 5A). Hence,  
463 patients with a high hypoxic fraction below this level had a poor outcome compared to the  
464 others ( $P=0.0014$ ; Fig. 5D). In contrast, weaker or no association to outcome was found for  
465 more severe hypoxia; *i.e.*, the highest  $HL_{MRI}$  values, or for milder hypoxia.

466


#### 467 **MR images distinguish hypoxia levels of biological significance**

468 The data set of hypoxic fractions generated in the above analysis was further correlated with  
469 gene expression profiles of the patient tumors to identify possible associations between  
470 hypoxia levels and biological processes. Totally 1344 genes showed a positive correlation  
471 ( $P<0.05$ ) for one or more  $HL_{MRI}$  thresholds and were included in a hallmark enrichment  
472 analysis. Out of 50 hallmarks, 36 were found to be significantly enriched (Supplementary  
473 Table S2), and 350 of the 1344 genes were included in one or more of these hallmarks. By  
474 assigning the  $HL_{MRI}$  threshold showing the strongest correlation between hypoxic fraction  
475 and expression ( $P<0.05$ ) for the 350 genes, a distribution of hypoxia levels was produced for  
476 each of the 36 enriched hallmarks. In general, the individual  $HL_{MRI}$  distributions covered a  
477 large range of hypoxia levels, and most hallmarks ( $n=26$ ) had a median  $HL_{MRI}$  in the  
478 moderate hypoxia range, including well known hypoxia regulated processes like hypoxia and  
479 glycolysis (Supplementary Figure S7, S8).

480


481 The  $HL_{MRI}$  distributions were further compared across the 36 hallmarks, to search for  
482 differences in the hypoxia level associated with biological processes. All hallmarks were  
483 tested against each other, and those with a difference ( $P<0.05$ ) to less than 25% of the  
484 others were removed to simplify analysis. For the remaining 15 hallmarks, three groups with  
485 a significant difference in  $HL_{MRI}$  distribution was identified (Fig. 6A; Supplementary Figure  
486 S7). A group with the interferon  $\alpha$  and  $\gamma$  response hallmarks was associated with mild  
487 hypoxia (Fig. 6A, B). At moderate levels, a group including  $G_2/M$  checkpoint, MYC targets,  
488 oxidative phosphorylation and MTORC1 signalling appeared significant, whereas hallmarks

489 like TNFA signalling via NFKB, DNA repair, inflammatory response, angiogenesis and EMT  
 490 were associated with the most severe levels.



491  
 492 **Figure 6.** Hypoxia levels in patient tumors in relation to cancer hallmarks. **A**, Correlation  
 493 analysis showing three distinct groups of hallmarks with significant difference in  $HL_{MRI}$   
 494 distribution, each related to either mild, moderate or severe hypoxia. P-values from  
 495 Wilcoxon rank sum test are shown (right). **B**, Cumulative  $HL_{MRI}$  distribution associated with a  
 496 selection of the hallmarks identified in **A**. Fraction of correlated genes in the hallmark is  
 497 summarized at each  $HL_{MRI}$  interval of 0.0004. Significant different  $HL_{MRI}$  distributions are  
 498 shown in each panel.

499  
 500  
 501 The data set of hypoxic fractions used for the analysis in Figure 5C was also included in a  
 502 correlation analysis against HIF1A protein level assessed by immunohistochemistry (Fig. 7A).  
 503 A strong correlation between HIF1A level and hypoxic fraction was found for a  $HL_{MRI}$   
 504 threshold of -0.21 (P=0.0021) (Fig. 7B), which was in the interval for mild hypoxia. This  $HL_{MRI}$   
 505 value was related to the cell line derived hypoxia activation level of 2.2%  $O_2$  (Fig. 5A), which  
 506 is comparable to the findings for HIF1A stabilization in experimental studies (8,9). Moreover,  
 507 the  $HL_{MRI}$  of -0.21 was outside the range for which a significant association to treatment  
 508 outcome was found (Fig. 5C), consistent with results from survival analysis based on HIF1A  
 509 protein (Fig. 7C). Taken together, by our imaging method it appeared possible to distinguish  
 510 hypoxia levels with association to different biological processes like cancer hallmarks and  
 511 HIF1A stabilization.



**Figure 7.** Hypoxia levels in patient tumors in relation to HIF1A protein level. **A**, Staining of HIF1A protein in a tumor with high (right) and low (left) protein level. **B**,  $P$ -value in correlation analysis of HIF1A protein level versus hypoxic fraction calculated for increasing  $HL_{MRI}$  threshold (increasing severity level) in 73 patients, plotted as a function of  $HL_{MRI}$ . Stippled line indicates  $HL_{MRI}$  for the strongest correlation ( $HL_{MRI}=-0.21$ ). **C**, Kaplan Meier curves for progression-free survival of 73 patients with low (solid line) and high (stippled line) level of HIFA protein. Patients were divided in two groups based on the pathology score, 0-3 and 4-5, to obtain approximately 1/3 in the high-risk and 2/3 in the low-risk group.  $P$ -value in log-rank test is shown.

538

539

540

## 541 Discussion

542

543 We here present a method based on diagnostic MRI to visualize hypoxia levels in patient  
544 tumors. Previous imaging methods have focused solely on the presence of hypoxia without  
545 considering its severity (15). By utilizing the CSH-tool to combine multiparametric images,  
546 we obtained the weighted information of oxygen consumption and supply that visualized a  
547 continuous range of hypoxia levels. Although adding more information like cellular  
548 proliferation rate or blood oxyhemoglobin saturation may improve the technology,  
549 comparison of our results with direct measures of hypoxia levels by pimonidazole staining

550 and indirect measures by gene expression showed strong correlations and validated the  
551 method. The hypoxia levels were found to differ in their association to treatment outcome  
552 and cancer hallmarks in cervical cancer, demonstrating that new understanding of how  
553 various levels affects tumor aggressiveness and biology can be achieved by our method. Our  
554 approach is easily applicable in the hospital's diagnostic procedures, and is a step towards a  
555 better exploitation of MR images in the clinic.

556  
557 Our algorithm to calculate hypoxia levels from MR images was validated in xenograft tumors  
558 by using pimonidazole staining intensity in histological sections as direct measure of hypoxia  
559 level. This approach was justified by our observation of a steady decrease in staining  
560 intensity away from necrosis. Binding of pimonidazole or other nitroimidazole compounds in  
561 cells or pieces of tumor tissue cultured *in vitro* under increasing oxygen concentrations has  
562 been shown to decrease in the same manner (24,26,27). Moreover, similar staining intensity  
563 gradients from necrosis have been quantified in tumor sections both by light and  
564 fluorescence microscopy (28,29). It is therefore likely that the intensity gradients in our  
565 histological sections reflected true differences in hypoxia levels. Further, by using large scale  
566 similarity analysis of hypoxic fractions obtained from MRI and pimonidazole staining,  
567 followed by correlation analysis of the corresponding levels, the linear range for reliable  
568 detection of hypoxia levels in xenograft tumors was obtained.

569  
570 The algorithm was confirmed in patient tumors by using an indicator of hypoxia levels based  
571 on gene expression. We utilized that some genes are upregulated at specific levels because  
572 they primarily are involved in biological processes activated under these conditions (6). The  
573 hypoxia activation level has been assessed previously for the HIF1A protein as the oxygen  
574 concentration for half-maximal response in cell lines (8). The same strategy was applied on  
575 our gene expression data to construct a panel of indicator genes with different activation  
576 level. Strict criteria for gene selection, based on expression responses in two cell lines  
577 exposed to a range of oxygen concentrations and correlation analysis of expression and  
578 imaging data in patient tumors, revealed nine suitable indicator genes. Indeed, a strong  
579 linear relationship between the cell line derived hypoxia activation levels and  $HL_{MRI}$  was  
580 found, confirming that a continuous range of hypoxia levels could be visualized in patient  
581 tumors.

582

583 Caution should be taken to directly transfer the oxygen concentrations for activation of  
584 genes in cell lines to hypoxia levels in patient tumors, however, it would enable a rough  
585 comparison of our results with existing pO<sub>2</sub> data of cervical cancer. The median MRI-defined  
586 hypoxia level for all tumors combined corresponded to a cell line derived level of 1.3% O<sub>2</sub>,  
587 which is within the range of 3-17 mmHg (approximately 0.4-2.2%) achieved by oxygen  
588 electrodes (14). Moreover, the strongest correlation to treatment outcome was found for a  
589 level corresponding to 0.7% O<sub>2</sub> based on cell line data. This is highly consistent with most  
590 pO<sub>2</sub> studies, reporting association to outcome for hypoxic fraction below 5 mmHg  
591 (approximately 0.7% O<sub>2</sub>) (14). Our approach therefore seemed to indicate hypoxia levels in  
592 accordance with oxygen electrode measurements, and to distinguish levels shown to be of  
593 prognostic significance in previous work.

594

595 Hypoxia levels associated with biological processes like cancer hallmarks and stabilization of  
596 HIF1A protein were identified by our method. At moderate hypoxia, which was the level  
597 most strongly correlated with treatment outcome, hallmarks like oxidative phosphorylation,  
598 targets of the MYC oncogene and G<sub>2</sub>/M checkpoint, appeared significant. This finding is  
599 consistent with our previous work where we identified a treatment resistant cervix tumor  
600 phenotype associated with the same hallmarks (30). In addition, this tumor phenotype  
601 appeared to have increased mitochondrial and proliferative activity (30). This implies that  
602 the stronger correlation of moderate hypoxia levels with poor outcome could be because  
603 hypoxic cells still have enough oxygen to proliferate under these conditions, in line with a  
604 hypothesis proposed by others (10,31). Stabilization of HIF1A protein, on the other hand,  
605 appeared significant at mild hypoxia levels, consistent with previous reports (6), and showed  
606 no correlation to outcome.

607

608 At severe hypoxia, the DNA repair hallmark appeared significant, consistent with studies  
609 showing activation of DNA damage response at extremely low oxygen concentrations (32).  
610 Our finding that inflammatory response and EMT were associated with such severe levels,  
611 on the other hand, is less well documented. It is tempting to speculate that this could be a  
612 consequence of lactate accumulation due to near complete vascular shut down in regions  
613 with severe hypoxia. Lactate is a key molecule in the inflammatory immune suppressive

614 response in tumors (33,34), and such inflammatory environment is a strong inducer of EMT  
615 (35). Although these novel associations for the most severe levels need to be explored  
616 further in experimental work, the findings demonstrate a potential of our method to achieve  
617 better insight into the hypoxic tumor phenotype.

618  
619 Our method to visualize hypoxia levels proposes a new application of routinely acquired  
620 DCE-MR images that may have implications for the diagnostic evaluation of patients. The  
621 finding that the CSH-tool could be used for this purpose, broadens the utility of the tool. This  
622 encourages investigations of hypoxia levels in other cancer types as well, by exploiting the  
623 MR technology already available at most hospitals. Our method provides a well needed  
624 opportunity to investigate the importance of individual hypoxia levels in tumor progression  
625 that eventually may lead to new and more efficient therapeutic options to combat hypoxia.

626

#### 627 **Disclosure and potential conflicts of interest**

628 No potential conflicts of interest were disclosed.

629

#### 630 **Acknowledgment**

631 Technical assistance from D. Trinh, Department of Pathology, is highly appreciated.

632

633



634 **References**

635

636

637 1. Horsman MR, Vaupel P. Pathophysiological basis for the formation of the tumor  
638 microenvironment. *Front Oncol.* 2016;6:66.

639 2. McKeown SR. Defining normoxia, physoxia and hypoxia in tumours—implications for  
640 treatment response. *Br J Radiol.* 2014;87:20130676.

641 3. Hunter FW, Wouters BG, Wilson WR. Hypoxia-activated prodrugs: paths forward in the  
642 era of personalised medicine. *Br J Cancer.* 2016;114:1071–7.

643 4. Ye Y, Hu Q, Chen H, Liang K, Yuan Y, Xiang Y, *et al.* Characterization of hypoxia-  
644 associated molecular features to aid hypoxia-targeted therapy. *Nat Metab.*  
645 2019;1:431–44.

646 5. Hockel M, Vaupel P. Tumor Hypoxia: Definitions and current clinical, biologic, and  
647 molecular aspects. *JNCI J Natl Cancer Inst.* 2001;93:266–76.

648 6. Koumenis C, Wouters BG. “Translating” tumor hypoxia: Unfolded protein response  
649 (UPR)-dependent and UPR-independent pathways. *Mol Cancer Res.* 2006;4:423–36.

650 7. Rademakers SE, Span PN, Kaanders JHAM, Sweep FCGJ, van der Kogel AJ, Bussink J.  
651 Molecular aspects of tumour hypoxia. *Mol Oncol.* 2008;2:41–53.

652 8. Jiang BH, Semenza GL, Bauer C, Marti HH. Hypoxia-inducible factor 1 levels vary  
653 exponentially over a physiologically relevant range of O<sub>2</sub> tension. *Am J Physiol.*  
654 1996;271:C1172-1180.

655 9. Bracken CP, Fedele AO, Linke S, Balrak W, Lisy K, Whitelaw ML, *et al.* Cell-specific  
656 regulation of hypoxia-inducible factor (HIF)-1 $\alpha$  and HIF-2 $\alpha$  stabilization and  
657 transactivation in a graded oxygen environment. *J Biol Chem.* 2006;281:22575–85.

658 10. Hoogsteen IJ, Marres HAM, Wijffels KIEM, Rijken PFJW, Peters JPW, van den Hoogen  
659 FJA, *et al.* Colocalization of carbonic anhydrase 9 expression and cell proliferation in  
660 human head and neck squamous cell carcinoma. *Clin Cancer Res.* 2005;11:97–106.

- 661 11. Luoto KR, Kumareswaran R, Bristow RG. Tumor hypoxia as a driving force in genetic  
662 instability. *Genome Integr.* 2013;4:5.
- 663 12. Triner D, Shah YM. Hypoxia-inducible factors: a central link between inflammation and  
664 cancer. *J Clin Invest.* 2016;126:3689–98.
- 665 13. Gort EH, Groot AJ, van der Wall E, van Diest PJ, Vooijs MA. Hypoxic regulation of  
666 metastasis via hypoxia-inducible factors. *Curr Mol Med.* 2008;8:60–7.
- 667 14. Vaupel P, Höckel M, Mayer A. Detection and characterization of tumor hypoxia using  
668 pO<sub>2</sub> histography. *Antioxid Redox Signal.* 2007;9:1221–36.
- 669 15. Horsman MR, Mortensen LS, Petersen JB, Busk M, Overgaard J. Imaging hypoxia to  
670 improve radiotherapy outcome. *Nat Rev Clin Oncol.* 2012;9:674–87.
- 671 16. Hompland T, Hole KH, Ragnum HB, Aarnes E-K, Vlatkovic L, Lie AK, *et al.* Combined MR  
672 imaging of oxygen consumption and supply reveals tumor hypoxia and aggressiveness  
673 in prostate cancer patients. *Cancer Res.* 2018;78:4774–85.
- 674 17. Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome.  
675 *Cancer Metastasis Rev.* 2007;26:225–39.
- 676 18. Lyng H, Malinen E. Hypoxia in cervical cancer: from biology to imaging. *Clin Transl*  
677 *Imaging.* 2017;5:373–88.
- 678 19. Tofts PS, Brix G, Buckley DL, Evelhoch JL, Henderson E, Knopp MV, *et al.* Estimating  
679 kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusible  
680 tracer: standardized quantities and symbols. *J Magn Reson Imaging JMRI.* 1999;10:223–  
681 32.
- 682 20. Fjeldbo CS, Julin CH, Lando M, Forsberg MF, Aarnes E-K, Alsner J, *et al.* Integrative  
683 analysis of DCE-MRI and gene expression profiles in construction of a gene classifier for  
684 assessment of hypoxia-related risk of chemoradiotherapy failure in cervical cancer. *Clin*  
685 *Cancer Res.* 2016;22:4067–76.



- 686 21. Halle C, Andersen E, Lando M, Aarnes E-K, Hasvold G, Holden M, *et al.* Hypoxia-induced  
687 gene expression in chemoradioresistant cervical cancer revealed by dynamic contrast-  
688 enhanced MRI. *Cancer Res.* 2012;72:5285–95.
- 689 22. Danaher P, Warren S, Dennis L, D’Amico L, White A, Disis ML, *et al.* Gene expression  
690 markers of tumor infiltrating leukocytes. *J Immunother Cancer.* 2017;5:18.
- 691 23. Zahra MA, Hollingsworth KG, Sala E, Lomas DJ, Tan LT. Dynamic contrast-enhanced MRI  
692 as a predictor of tumour response to radiotherapy. *Lancet Oncol.* 2007;8:63–74.
- 693 24. Arteel G, Thurman R, Yates J, Raleigh J. Evidence that hypoxia markers detect oxygen  
694 gradients in liver: pimonidazole and retrograde perfusion of rat liver. *Br J Cancer.*  
695 1995;72:889–95.
- 696 25. Sørensen BS, Hao J, Overgaard J, Vorum H, Honoré B, Alsner J, *et al.* Influence of oxygen  
697 concentration and pH on expression of hypoxia induced genes. *Radiother Oncol.*  
698 2005;76:187–93.
- 699 26. Urtasun RC, Chapman JD, Raleigh JA, Franko AJ, Koch CJ. Binding of 3H-misonidazole to  
700 solid human tumors as a measure of tumor hypoxia. *Int J Radiat Oncol.* 1986;12:1263–  
701 7.
- 702 27. Koch CJ, Evans SM, Lord EM. Oxygen dependence of cellular uptake of EF5 [2-(2-nitro-  
703 1H-imidazol-1-yl)-N-(2,2,3,3,3-pentafluoropropyl)acetamide]: analysis of drug adducts  
704 by fluorescent antibodies vs bound radioactivity. *Br J Cancer.* 1995;72:869–74.
- 705 28. Zaidi M, Fu F, Cojocari D, McKee TD, Wouters BG. Quantitative visualization of hypoxia  
706 and proliferation gradients within histological tissue sections. *Front Bioeng Biotechnol.*  
707 2019;7:397.
- 708 29. Sundstrom A, Grabocka E, Bar-Sagi D, Mishra B. Histological image processing features  
709 induce a quantitative characterization of chronic tumor hypoxia. *PLOS ONE.*  
710 2016;11:e0153623.

- 711 30. Jonsson M, Fjeldbo CS, Holm R, Stokke T, Kristensen GB, Lyng H. Mitochondrial function  
712 of CKS2 oncoprotein links oxidative phosphorylation with cell division in  
713 chemoradioresistant cervical cancer. *Neoplasia*. 2019;21:353–62.
- 714 31. Wouters BG, Brown JM. Cells at intermediate oxygen levels can be more important  
715 than the “hypoxic fraction” in determining tumor response to fractionated  
716 radiotherapy. *Radiat Res*. 1997;147:541–50.
- 717 32. Ng N, Purshouse K, Foskolou IP, Olcina MM, Hammond EM. Challenges to DNA  
718 replication in hypoxic conditions. *FEBS J*. 2018;285:1563–71.
- 719 33. Hirschhaeuser F, Sattler UGA, Mueller-Klieser W. Lactate: A metabolic key player in  
720 cancer. *Cancer Res*. 2011;71:6921–5.
- 721 34. Pucino V, Bombardieri M, Pitzalis C, Mauro C. Lactate at the crossroads of metabolism,  
722 inflammation, and autoimmunity. *Eur J Immunol*. 2017;47:14–21.
- 723 35. Suarez-Carmona M, Lesage J, Cataldo D, Gilles C. EMT and inflammation: inseparable  
724 actors of cancer progression. *Mol Oncol*. 2017;11:805–23.
- 725